Autosomal dominant Alzheimer's disease (AD) has informed the field of AD research about the molecular and biochemical mechanisms that are believed to underlie the pathological basis of AD. Further, mutations from autosomal dominant AD have provided animal and cellular models that are utilized to develop anti-A? drugs. Due to the rarity of autosomal dominant AD, the Dominantly Inherited Alzheimer Network (DIAN; U01 AG032438) was launched in 2008 to establish an international, multicenter registry of individuals at risk or with a known causative mutation of AD in the amyloid precursor protein (APP), presenilin 1 (PS1), or presenilin 2 (PS2) genes. DIAN evaluates participants at entry and longitudinally thereafter with clinical and cognitive batteries, structural, functional, metabolic,and amyloid imaging protocols, and biological fluid (blood; cerebrospinal fluid) collection with the goal of determining the sequence of imaging and biomarker changes in presymptomatic gene carriers who are destined to develop AD. Because the clinical and pathological phenotypes of dominantly inherited AD appear similar to those for the far more common late-onset sporadic AD, the nature and sequence of brain changes in dominantly inherited AD are also likely relevant for sporadic AD. The trial design is a randomized, blinded placebo controlled four arm trial of a fibrillar anti-A? antibody, a soluble anti-A? antibody, and a beta-secretase inhibitor i 160 (n=40 per arm) asymptomatic to mildly symptomatic ADAD mutation carriers. Subjects will receive either drug of placebo for two years to determine engagement of the CNS mechanism of action and downstream AD biomarkers.

Public Health Relevance

The proposed grant will initiate a trial of 3 anti-amyloid drugs in individuals with known causative mutations for dominantly inherited Alzheimer's disease (AD). Although this dominantly inherited form of AD is rare, the symptoms and brain changes are similar to those observed in the far more common late-onset sporadic AD. The results of the trial provides a test of the amyloid hypothesis, and may delay, prevent or reverse cognitive impairment from AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG042791-04S2
Application #
9751508
Study Section
Neuroscience of Aging Review Committee (NIA)
Program Officer
Mclinden, Kristina
Project Start
2013-09-20
Project End
2019-06-30
Budget Start
2018-09-01
Budget End
2019-06-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Wang, Guoqiao; Berry, Scott; Xiong, Chengjie et al. (2018) A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med 37:3047-3055
Clifford, David B (2017) HIV-associated neurocognitive disorder. Curr Opin Infect Dis 30:117-122
Roe, Catherine M; Babulal, Ganesh M; Head, Denise M et al. (2017) Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y) 3:74-82
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2017) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord 31:69-72
Raman, Mekala R; Tosakulwong, Nirubol; Zuk, Samantha M et al. (2017) Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. J Hypertens 35:2479-2485
Natelson Love, Marissa; Clark, David G; Cochran, J Nicholas et al. (2017) Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiol Aging 49:216.e7-216.e13
Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2017) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13:8-19
Raman, Mekala R; Schwarz, Christopher G; Murray, Melissa E et al. (2016) An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. J Neuroimaging 26:264-8
Weninger, Stacie; Carrillo, Maria C; Dunn, Billy et al. (2016) Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement 12:631-2
Wang, Fen; Gordon, Brian A; Ryman, Davis C et al. (2015) Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology 85:790-8

Showing the most recent 10 out of 14 publications